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Abstract: Somatic cell genetic alterations are a hallmark of tumor development and progression. Although various technologies have 
been developed and utilized to identify genetic aberrations, identifying genetic translocations at the chromosomal level is still a chal-
lenging task. High density SNP microarrays are useful to measure DNA copy number variation (CNV) across the genome. Utilizing SNP 
array data of cancer cell lines and patient samples, we evaluated the CNV and copy number breakpoints for several known fusion genes 
implicated in tumorigenesis. This analysis demonstrated the potential utility of SNP array data for the prediction of genetic aberrations 
via translocations based on identifying copy number breakpoints within the target genes. Genome-wide analysis was also performed to 
identify genes harboring copy number breakpoints across 820 cancer cell lines. Candidate oncogenes were identified that are linked to 
potential translocations in specific cancer cell lines.
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Background
One of the major goals in cancer research is to iden-
tify causal genetic aberrations. This has led to the 
identification  of  several  successful  therapeutic  tar-
gets,  including  BCR-ABL  fusion,  EGFR  amplifi-
cation/mutation,  and  HER2  amplification.  Among 
different types of genetic aberrations, chromosomal 
rearrangements creating oncogenic gene fusions are 
the hallmark of many haematopoietic malignancies 
as well as rare bone and soft-tissue tumors.1,2 Recent 
reports  suggest  that  many  solid  tumors  also  con-
tain gene fusions that confer tumorigenic potential. 
  Multiple  methods  were  developed  for  identifying 
gene fusions caused by chromosomal translocations. 
Traditional methods involve cytogenetic analysis fol-
lowed by fluorescent in situ hybridization analysis. 
Recent high-throughput data platforms also provide 
opportunities to discover novel fusions. For example, 
expression data based analysis such as Cancer Outlier 
Profile Analysis  (COPA)3  identified  novel  fusions, 
including TMPRSS2-ERG and TMPRSS2-ETV1 in 
prostate cancer.4 Deep sequencing of cDNA librar-
ies led to the discovery of the EML4-ALK fusion in 
non-small-cell lung cancer (NSCLC),1 and integra-
tive analysis of high-throughput long- and short-read 
transcriptome  sequencing  identified  several  gene 
fusions in prostate cancer cell lines.5 However, since 
these methods are based on information from RNA 
transcripts, the fusion identified might be due to alter-
native  splicing,  or  transcript  level  re-arrangement. 
Identifying translocations at the chromosomal level 
remains a challenging task.
Chromosomal translocations, by definition, alter 
genomic sequences, and may generate fusion proteins 
or dysregulate gene expression. Chromosomal trans-
locations elicit DNA repair processes, which involve 
mis-repair of double-strand ends. Cloning genomic 
junctions in various chromosome translocations in leu-
kemia shows that there are deletions, duplications, and 
insertions at the breakpoints in many   translocations.6 
The sizes of deletions and duplications range from a 
few bp to a few hundred bp. Many fusion genes are 
also reported to have multiple copies. These will result 
in copy number variation (CNV) between segments 
retained in the fusion gene and its neighboring genomic 
sequences. High density SNP arrays are useful tools 
not  only  to  study  SNP-based  genetic  linkage,  but 
also to detect DNA CNV across the whole genome. 
The current Affymetrix SNP array 6.0 contains 1.8 
million  markers  for  genetic  variation,  and  has  a 
median inter-marker distance of less than 700 bases. 
During the last few years, extensive efforts have been 
dedicated to SNP array profiling on tumor samples 
and cell lines. For example, the Sanger Institute has 
profiled over 800 cancer cell lines on the Affyme-
trix SNP array 6.0. We postulate that if a deletion or 
duplication exists at the breakpoint/junction site of a 
gene fusion event during tumorigenesis, or if a fusion 
gene is amplified to have multiple copies, then there 
is likely to be a copy number breakpoint juxtaposed 
to the genomic junction of the fusion gene, which can 
be detected by high-resolution SNP arrays.
We validated this hypothesis by analyzing three 
well-known genetic fusions in cancer: BCR-ABL1, 
TMPRSS2-ERG, and EML4-ALK using high density 
SNP array data from related patient samples and can-
cer cell lines. We examined whether there is a copy 
number breakpoint near or at the junction of each 
fusion gene. Two aspects were evaluated: (i) whether 
a deletion or amplification in copy number could be 
detected, and (ii) the distance relative to the specific 
fusion junction. Based on the information from the 
analysis of the validation set, we developed a search 
tool to identify additional cancer cell lines that may 
contain interesting fusion genes, by examining the 
SNP  array  data  of  Sanger’s  820  cancer  cell  lines. 
Finally, we evaluated the distribution of gene-linked 
copy number breakpoints in cancer cell lines. Based 
on these efforts, we provide a framework for evaluat-
ing and possibly detecting translocation mutations in 
different cancers utilizing SNP array data.
Results
Analyzing known gene fusions utilizing 
SNP array data
Case 1: BCR-ABL
examination of CML cell lines with reported Philadelphia 
chromosome translocations
The BCR-ABL gene fusion, also referred to as the Phil-
adelphia chromosome or Philadelphia translocation, 
is the best known chromosomal abnormality result-
ing from a reciprocal translocation between chromo-
some 9 and 22. The fusion contains 5´end sequences 
from BCR and 3´end sequences from ABL1, which 
contains  the  kinase  domain.  The  chimeric  BCR-
ABL  protein  has  constitutively  elevated  tyrosine 
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phosphokinase  activity.  This  abnormal  enzymatic 
activation  is  critical  to  the  oncogenic  potential  of 
BCR-ABL.7 It is found in 95% of the subjects with 
CML, in 25%–30% of ALL patients, and occasion-
ally in AML patients.7
Among the 820 cell lines that the Sanger Institute 
profiled, there are eight cell lines that are of CML ori-
gin with reported Philadelphia chromosomes: MEG01, 
K562, BV173, EM2, LAMA84, NALM1, CMLT-1, 
and KU812. We analyzed the SNP array data of these 
cell lines and observed that five cell lines (MEG01, 
K562,  BV173,  EM2,  and  LAMA84)  contain  copy 
number breakpoints in both the BCR and ABL1 genes 
(Fig. 1). There are three known breakpoint cluster 
regions in BCR. The majority of breakpoints in CML 
patients have been reported to occur between BCR 
exons 12 to 16. The second breakpoint cluster region, 
mainly in ALL, lies within an intron between BCR 
exons 1 and 2, while the third one is located down-
stream of BCR exon 19.8 In the five CML cell lines in 
which copy number breakpoints were observed, the 
breakpoints in BCR all reside between exons 12 to 16, 
while the breakpoints in ABL1 vary somewhat, but 
the majority reside within the first intron. As for the 
CNV, in BCR, the copy number at its 3´end is lower 
than that of its 5´end, while in ABL1, the copy num-
ber at its 3´end is always higher than that of its 5´end, 
thus favoring presence of BCR-ABL fusion protein. 
As  for  the  other  three  CML  cell  lines  (NALM1, 
CMLT-1, and KU812), breakpoints were detected in 
either BCR, ABL1, or in the neighboring regions. For 
example, in CMLT-1 cells, a copy number breakpoint 
was found in ABL1, while in KU812 a micro-deletion 
was found in ABL1. Of note, CNV were found in 
the neighbor genes of BCR in all three cell lines. 
In conclusion, although the number of examples is 
limited, the copy numbers for sequences that retain 
in the fusion gene are either remained as normal or 
increased, but are never decreased; while the copy 
numbers for sequences that are not in the fusion gene 
are  either lost  or remain as  normal, but are  never 
increased.
In order to evaluate CNV in the coding regions, 
especially in the oncogenes, we searched the copy 
Figure 1. Genomic level CNV analysis of BCR and ABL1 genes using Affymetrix SNP 6.0 array data for eight CML cell lines. Copy number states are 
divided into the following categories: 0-homozygous deletion; 1-heterozygous deletion; 2-normal diploid; 3-single copy gain; and 4-multiple copy gain. 
Arrows highlight both amplified (blue) and deleted (red) genomic segments. 
notes: Black arrow indicates the direction of the transcript. Affymetrix Genotyping Console software was used for this analysis.
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number breakpoint resides within the transcript of the 
oncogene in these eight CML cell lines. As shown in 
supplemental Table 1, ABL1 contains copy number 
breakpoints in six out of the eight CML cell lines. 
The frequency (75%) is the highest compared to other 
oncogenes.
Searching for other cancer cell types with potential  
BCR-ABL1 fusions
We asked whether copy number breakpoints occur 
within  BCR  and  ABL1  in  cancer  cells  of  non-
  hematopoietic origins. By analyzing the Sanger 820 
cell line panel, we identified two cell lines that con-
tain breakpoints in both BCR and ABL1 (Fig. 2). 
The breakpoint within BCR in NCI-H747, a colon 
cancer  cell  line,  was  similar  to  that  of  the  other 
CML cell lines, residing between exons 12 to 16. 
However, in NCI-H1581, a lung cancer cell line, the 
breakpoint was between exons 1 and 2, similar to 
that of ALL. In NCI-H747, the CNV was consistent 
with what was observed in the other CML cell lines: 
namely, the copy number at 3´end is lower than that 
of 5´end for BCR, and the copy number at 3´end 
is higher than that of 5´end for ABL1. However, in 
NCI-H1581, the CNV in ABL1 is different, with the 
3´end (containing the kinase domain) at lower copy 
number  relative  to  the  5´end.  Whether  these  cell 
lines contain a functional BCR-ABL fusion is yet to 
be determined.
To evaluate the random chance to identify copy 
number breakpoints in both BCR and ABL1 genes 
in  a  given  cell  line,  simulations  were  performed 
by  assigning  the  information  of  all  amplification 
or loss segments, such as the segment length, copy 
number status (gain or loss) from either NCI-H1581 
or NCI-H747, on a hypothetic genome. For each 
cell  line,  the  simulation  was  performed  100,000 
times, and no breakpoint was found in both BCR 
and ABL1 in a single case. This suggests that the 
chance to observe copy number breakpoints in both 
BCR and ABL1 in the two cell lines is unlikely to 
occur by chance alone.
Case 2: TMPrSS2-erg
examination of prostate cancer samples and cell lines
Recent findings, through a bioinformatics approach 
(COPA),3  revealed  that  prostate  cancers  frequently 
over-express the ETS family transcription factors ERG 
and ETV1 as a result of chromosomal rearrangements 
that lead to the fusion of the 5´end of the androgen-
regulated serine protease TMPRSS2 (21q22.2) to the 
3´end of either ERG (21q22.3) or ETV1 (7p21.3).4 
The consequence is the aberrant androgen receptor-
driven expression of the potential oncogenes ERG or 
ETV1. The TMPRSS2-ERG fusion is present at high 
frequency in moderate to poorly differentiated pros-
tate cancers (35/86, 40.7%),9 in contrast to TMPRSS2-
ETV1 which is the product of a rare fusion event.
We evaluated whether SNP data could be reveal 
insights  about  the  mechanisms  involved  in  these 
fusion events in prostate cancer. To this end, we ana-
lyzed the SNP array data of 20 paired prostate cancer 
Figure 2. Affymetrix Genotyping Console Browser view of BCR and ABL1 genes for two non-CML cell lines that possess copy number breakpoints in both 
BCR and ABL1 genes. Copy number states are divided into the following categories: 0-homozygous deletion; 1-heterozygous deletion; 2-normal diploid; 
3-single copy gain; and 4-multiple copy gain. 
notes: Arrows highlight both amplified (blue) and deleted (red) genomic segments. Black arrows indicate the direction of the transcript.
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samples with matched normal samples from GEO. 
Both TMPRSS2 and ERG are on the same chromo-
some, chromosome 21, and reside on the negative 
DNA strand with an invervening distance of 2.7 Mb. 
As shown in Figure 3, three out of 20 samples (15%) 
contain a segment deletion between TMPRSS2 and 
ERG. Although the positions of the breakpoints at 
both TMPRSS2 and ERG are different in the three 
samples, the final fusions retain the coding sequence 
of  ERG  linked  to  the  5’  regulatory  sequences  of 
TMPRSS2.  In  addition,  we  found  that  ETV1  was 
amplified in three of the 10 prostate samples (data 
not shown).
In order to evaluate CNV in the coding regions, 
especially in the oncogenes, we searched the copy 
number  breakpoint  resides  within  the  transcript  of 
the oncogene in these 20 prostate cancer samples. As 
shown in supplemental Table 2, ERG contains copy 
number breakpoints in three out of the 20 prostate 
cancer samples. The frequency (15%) is the highest 
compared to other oncogenes.
The TMPRSS2-ERG fusion is known to exist in 
the prostate cell line VCaP.5 However, we were unable 
to locate publicly available SNP array data for this 
cell line. Instead, we investigated prostate cell lines 
profiled by Sanger Institute. Among 820 cancer cell 
lines, five prostate cancer cell lines are represented: 
22RV, BPH-1, DU-145, LNCaP, PC-3. None of these 
lines possess segmental deletions between TMPRSS2 
and ERG, nor is the copy number of ETV1 amplified 
(data not shown).
Searching for other cancer cell types  
with the TMPrSS2-erg fusion
In order to assess whether the TMPRSS2-ERG fusion 
is unique to prostate cancers, a search was performed 
to identify other cell line containing segmental dele-
tions  between  ERG  and TMPRSS2.    Specifically,  we 
queried for a deletion segment with one end anchored 
either within TMPRSS2 or between TMPRSS2 and 
its  neighbor  RIPK4,  and  the  other  end  anchored 
either within the 5´end of ERG or between ERG 
and  its  neighbor  gene  ETS2.  This  type  of  dele-
tion has the potential to create a fusion gene that 
utilizes the promoter of TMPRSS2 and links to the cod-
ing of ERG. However, among the 820 cell lines that the 
Figure 3. Affymetrix Genotyping Console Browser view of the segment deletion between TMPRSS2 and ERG in prostate cancer samples. Copy number states 
are divided into the following categories: 0-homozygous deletion; 1-heterozygous deletion; 2-normal diploid; 3-single copy gain; and 4-multiple copy gain. 
notes: red arrows demarcate deleted genomic segments, while black arrows designate the directions of the two transcripts.
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Sanger Institute profiled, none contains such deletion. 
This is suggestive that the TMPRSS2-ERG fusion is 
restricted to specific subtypes of prostate cancers.
Case 3: eML4-ALK
examination of lung cancer cell lines
The EML4-ALK fusion was identified in a NSCLC 
sample by full-length cDNA cloning. It was also 
detected in other lung cancers with a frequency of 
9.1% (3 out of 33).1 To further evaluate the utility 
of SNP array data for identifying potential trans-
locations,  both  EML4  and  ALK  were  examined 
for potential copy number breakpoints in Sanger’s 
140 lung cancer cell lines. Among these 140 lung 
cancer  cell  lines,  six  (4%)  were  found  to  carry 
breakpoints for both EML4 and ALK. As shown in 
Figure 4, most of the copy number breakpoints in 
EML4 are caused by the amplification of the 5´end 
of the gene, while breakpoints in ALK are closer 
to its 3´end. This is consistent with the junctional 
sequence described for EML4-ALK, in which the 
5´end  sequence  of  EML4  is  linked  to  the  3´end 
sequence of ALK, where the kinase domain resides. 
A literature search revealed that, among these six 
lung  cancer  cell  lines,  NCIH2228  is  reported  to 
contain EML4-ALK fusion that links EML4 exon 6 
to ALK exon 20.10
In order to evaluate CNV in the coding regions, 
especially in the oncogenes, we searched the copy 
number breakpoint resides within the transcript of the 
oncogene in these 140 lung cancer cell lines. As shown 
in supplemental Table 3, ALK contains copy number 
breakpoints in 22 out of the 140 lung cancer cell lines. 
Its frequency (15.7%) is among the top ranked but 
not the highest. Among the ten oncogenes that have 
higher  copy  number  breakpoint  frequencies  than 
that of ALK, five of them: PVT1 (t(2;8) and t(8;22) 
in Burkitt lymphoma)11 AKT3 (t(1;13)(q44;q32) in 
microcephaly and agenesis of the corpus callosum),12 
VAV2  (t(1;9)(p36.32;q34.2)  in  bilateral  exotropia, 
left ptosis)13 ABL2 (t(1;12)(q25;p13) in AML),14 and 
NTRK3 (t(12;15)(p13;q25) in salivary gland tumors 
and AML),15,16 were reported to be involved in recip-
rocal translocation. It will be of interest to validate 
whether  these  translocations  are  also  present  in 
the lung cancer cell lines.
Figure 4. Affymetrix Genotyping Console Browser view of EML4 and ALK genes in six lung cancer cell lines that contain copy number breakpoints in both 
genes. Copy number states are divided into the following categories: 0-homozygous deletion; 1-heterozygous deletion; 2-normal diploid; 3-single copy 
gain; and 4-multiple copy gain. 
notes: Arrows highlight both amplified (blue) and deleted (red) genomic segments. Black arrows indicate the directions of the transcripts. The numbers 
in brackets indicate the P values.
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Searching for additional cancer cell lines  
with eML4-ALK fusions
We  further  searched  for  cell  lines  carrying  break-
points  for  both  EML4  and ALK  by  surveying  the 
entire 820 Sanger cell lines, and identify an addi-
tional 18 cell lines that carry copy number break-
points similar to those of the six lung cell lines. As 
shown in Table 1, these cell lines are from different 
cancer origins, including breast, skin, stomach, and 
colon. Calculated P values suggest that it is highly 
unlikely that copy number breakpoints within both 
EML4 and ALK in there cell lines occur by random 
chance. This is in agreement with a report indicat-
ing that the EML4-ALK fusion is not only found in 
lung cancer samples, but also in other cancers such 
as breast and colorectal.17 It is worth noting that this 
fusion sequence was detected by RT-PCR assay in the 
colon cell line SW1417.17
Identifying oncogenes with copy  
number breakpoints
A proto-oncogene can become an oncogene as a con-
sequence of a relatively small modification such as 
mutations  or  increased  expression.  Chromosomal 
rearragement can lead to the increased gene expres-
sion,  or  the  expression  of  a  constitutively  active 
hybrid protein18 In order to identify cell lines carrying 
similar breakpoint as ABL1, we searched the CNV 
in  the  oncogenes  that  were  defined  by   Affymetrix 
chip annotation across Sanger’s 820 cancer cell lines 
according  to  the  following  criteria:  (1)  The  copy 
number  breakpoint  resides  within  the  transcript  of 
the oncogene; and (2) the copy number for the cod-
ing sequence is either normal (n = 2) or amplified, 
but not deleted. Among the 205 oncogenes annotated 
by Affymetrix,  26%  (54)  oncogenes  contain  copy 
number breakpoints in at least one cancer cell line 
  (Supplemental Table 4). This is substantially higher 
(P  value  =  0.001)  than  the  genome-wide  search, 
where we found that 17% (2,945 of out total 17,609) 
of the genes contain copy number breakpoint in at 
least one cancer cell line.
As a comparison, we further evaluated the copy 
number breakpoints of oncogenes and all genes in nor-
mal cell lines, which were converted from the blood 
samples of healthy donors collected by the Interna-
tional HapMap project. Based on the limited 38 Hap-
Map normal cell line data retrieved from GEO, none 
of the oncogenes contains copy number breakpoints, 
while only 0.1% (19 out of total 17,609) of the genes 
in the genome contain CNV in at least one normal 
cell line. There is no significant difference between 
oncogenes versus all genes (P value = 0.638) with 
regard to the frequency of copy number breakpoints 
in these normal cell lines.
genome-Wide evaluation  
of gene-linked copy number  
breakpoints in cancer cell lines
We sought to go beyond our initial analyses of onco-
genes and broadly evaluate copy number breakpoints 
across all genes for all 820 of the Sanger cancer cell 
lines. A gene was considered to contain a copy num-
ber breakpoint if the CNV was present within its tran-
script, regardless of the location or whether it was 
associated with amplification or deletion. The results 
of this analysis reveal that the mean value of the num-
ber of genes with copy number breakpoints in Sanger’s 
cancer lines is 369, which is much higher than the 
mean of 25 obtained for HapMap normal cell lines 
(P , = 4.054e-10). When the numbers of genes con-
taining copy number breakpoints were plotted against 
cancers of various tissue origins, a significant vari-
ability was observed amongst cancer origins. On one 
Table  1. Additional  Sanger’s  non-lung  cancer  cell  lines 
that contain breakpoints in both eML4 and ALK genes. 
cell line primary tissue P value
Saos-2 bone 0.002
MDA-MB-468 breast 0.017
UACC-893 breast 0.028
COLO-824 breast 0.004
KNS-42 brain 0.053
DoTc2-4510 cervix 0.042
DeL haematopoietic 0.011
LAMA-84 haematopoietic 0.03
SW403 colon 0.006
SW1417 colon 0.016
OVCAR-5 ovary 0.011
PANC-08-13 pancreas 0.013
A101D skin 0.009
ChL-1 skin 0.006
SK-MeL-5 skin 0.004
SCh stomach 0.008
MKN28 stomach 0.002
639-V urinary 0.009
note: P value indicates the random chance for the cell line to contain 
breakpoints in both eML4 and ALK.
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end of the spectrum, liver cancers and mesotheliomas 
possess medians of greater than 600 genes containing 
copy number breakpoints. In contrast, hematopoietic 
cancers exhibited a median of 70 genes containing 
copy number breakpoints (Fig. 5).
Discussion
In this study, we have utilized SNP array data and 
evaluated  three  well  known  fusion  genes  that  are 
associated  with  tumorigenesis  for  the  presence  of 
copy number breakpoints within genomic sequences.
For BCR-ABL1, we observed breakpoints in both 
BCR and ABL1 in 5 out of 8 CML cell lines. This 
suggests the potential limitation of detecting translo-
cations by using SNP array data, which may be attrib-
uted to a number of factors. First, the SNP array data 
can only detect gene fusions with underlying chro-
mosomal changes, and not copy neutral alterations, 
such as balanced translocations with no gain or loss 
of genetic information. Second, the lack of deletion/
duplication signatures at junctional sites in certain cell 
lines may due to the resolution of SNP array data if 
the deletion/duplication segment is relatively small. It 
should be noted that for the other three CML cell lines, 
breakpoints were present in either BCR, ABL1, or in 
the neighboring genes. Additional searches identified 
two non-leukemia cancer cell lines that also contain 
copy number breakpoints in BCR and ABL1. It will 
be of interest to confirm whether these two cell lines 
do contain BCR-ABL1 fusions since BCR-ABL1 has 
only been reported in leukemias to date.
For TMPRSS2-ERG,  based  on  the  20  prostate 
patient sample sets, the SNP array data reveal that 
some of the fusions are likely results of genomic 
sequence deletion. As for other Ets family members, 
such as ETV1, the altered expression may be due 
to different genetic mutations, such as gene ampli-
fication. Alternatively, the frequency of TMPRSS2-
ETV1  translocation  fusions  may  be  much  lower 
than for TMPRSS2-ERG. In this limited data set, 
the samples that contain amplified ETV1 and fusion 
ERG were mutually exclusive, which implies that 
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Figure 5. Boxplot view of the numbers of gene-linked copy number breakpoint in 820 cancer cell lines from different cancer origins. 
notes: The numbers in brackets indicate the number of cell lines mapped to each cancer type. Cancer types with less than 5 cell lines are not included.   
Y axis: the number of gene-linked copy number breakpoints. Median: bolded line inside the box; 25 percentile: top line of the box; 75 percentile: bottom 
line of the box; Maximum (excluding outliers): top bar outside of the box; Minimum (excluding outliers): lowest bar outside of the box; Outlier: O.
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the  over-  expression  of  one  of  the  Ets  genes  may 
contribute  to  initiation  or  progression  of  prostate 
cancer. Genome wide analysis indicates that none of 
the 820 Sanger cancer cell lines contain a segment 
deletion between TMPRSS2 and ERG similar to what 
we observed in the primary prostate cancer samples. 
There are two possibilities: (1) with only five pros-
tate cancer cell lines in the panel, the number is too 
small to represent the wide genetic diversity of pros-
tate cancers; (2) TMPRSS2-ERG is unique to pros-
tate  cancer,  since TMPRSS2  expression  is  almost 
exclusively  in  the  prostate  with  some  expression 
in the GI track. In addition, the fusion is regulated 
by androgen as TMPRSS2 expression is androgen 
dependent19,20 which provides it a growth advantage 
only in prostate and not in other tissues. However, 
we can not rule out other fusion transcript mecha-
nisms,  such  as  transcript  read-through,  which  can 
not be captured by SNP array data at the DNA level. 
This is all the more possible given that TMPRSS2 
and ERG are closely located on the same chromo-
some, and that read-through fusion transcripts were 
identified in prostate cancer.5
For the EML4-ALK fusion, we have identified 6 
lung cancer cell lines, and 18 cell lines from other can-
cer origins with copy number breakpoints. This is in 
agreement with a report by Lin et al, where a RT-PCR 
assay was used to examine a panel of 124 cell lines 
from breast cancer, colorectal cancer, and NSCLC for 
fusion transcripts of  EML4-ALK. With this panel, 9 cell 
lines,  including  a  known  positive  control  (H2228), 
were identified to harbor the EML4-ALK fusion. Since 
the detailed information of the 124 cell lines was not 
available in the publication, we were not able to com-
pare them with our copy number analysis. However, 
based on some of the positive and negative cell lines 
listed in the paper, we were able to evaluate nine cell 
lines that were common. Among them, two cell lines 
(H2228 and SW1417) are positive, and five cell lines 
(T47D,  CAL120,  HCT116,  H1299,  and  H838)  are 
negative supported by both methods. There are two 
cell lines (H460 and H1975), which were found to 
contain fusion transcripts, but do not show copy num-
ber breakpoints by SNP array data. This again suggests 
the potential limitation of detecting translocations by 
using SNP array data as discussed above.
In the above evaluations, we also assessed all copy 
number breakpoints in the coding regions, especially 
in the oncogenes. The frequencies of the copy number 
breakpoint for ABL1 (75%), ERG (15%) and ALK 
(15.7%) are high in the eight CML cell lines, 20 pros-
tate cancer samples, and 140 lung cancer cell lines, 
respectively. However, the frequency for ERG may be 
underestimated since the SNP array data of the pros-
tate cancer samples were generated from Affymetrix 
500 K array Set, whose probe coverage is less than one 
third of that of the Affymetrix array 6.0 used for the 
Sanger panel. In the CML cell lines and prostate cancer 
samples, the frequencies of copy number breakpoint 
for ABL1  and  ERG,  respectively,  were  ranked  top 
compared to other oncogenes. In the lung cancer cell 
lines, there are several oncogenes whose copy number 
breakpoint frequencies are higher than that of ALK. 
Some of them were reported to be involved in recip-
rocal translocation in other cancers or developmental 
diseases. Since the overall frequency of EML4-ALK 
fusion is low (9.1%) in lung cancers, other mechanisms 
including other fusions, may possibly be involved in 
these lung cancer cell lines. It will be of interest to 
further  experimentally  validate  the  potential  trans-
location candidates, which will help us to discover 
novel fusion and provide a better understanding of the 
false positive rate. For the potential utility of applying 
SNP array data to detect novel translocation fusion, 
we suggest that the focus should be on the oncogenes 
with high frequency of copy number breakpoints in 
the studied samples. The prediction can be powerful 
if the fusion gene is present at high frequency in the 
studied   samples. In conclusion, analyzing SNP array 
data for copy number breakpoint frequencies of onco-
genes could provide us a potential translocation candi-
date list to be further followed up experimentally.
Genome-wide  copy  number  breakpoint  analysis 
was also performed in the 820 Sanger cell lines. It had 
identified genes that contain copy number breakpoints 
in Sanger cancer cell lines, but not in the 38 Hapmap 
normal cell lines. We evaluated the top ten genes that 
are highly linked with copy number breakpoints only 
in the cancer cell lines (Supplemental Table 5). The 
genomic sizes of these genes tend to be very large, 
which may increase the chance for them to link with 
a copy number breakpoint.   Nevertheless, it is inter-
esting to note that five out of the ten genes: MAC-
ROD2
21  FHIT,22  CNTNAP2,23  MAGI2,24  LRP1B25 
were reported that were involved in genomic sequence 
re-arrangement/translocation.
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Many  cancer  cell  lines  have  extensive  in  vitro 
passage histories and therefore may accumulate addi-
tional mutations associated with extended laboratory 
propagation. Cancer cell lines, many of which have 
defective DNA repair machinery, are particularly sus-
ceptible to genetic alterations that confer growth or 
survival  advantages  under  conventional  tissue  cul-
ture conditions. In order to evaluate whether cancer 
lines  contain  greater  frequencies  of  translocation 
mutations, we assessed the gene-linked copy number 
breakpoints  in  primary  cancer  samples.  First,  we 
examined  the  number  of  genes  containing  copy 
number breakpoints in the 20 paired primary prostate 
cancer samples. The average value of 74 was signifi-
cantly lower (t-test with P value , = 0.0001) than 
the average value (= 462) of the five prostate can-
cer cell lines in the Sanger set. However, the number 
for the 20 primary prostate cancer samples may be 
underestimated due to the low density of SNP array 
used. Next, we examined a public data set from pri-
mary gastrointestinal stromal tumors (GIST) samples 
that were profiled on the same one million SNP array. 
In the 25 GIST samples, the average number for the 
gene linked copy number breakpoint is 239, and it is 
lower but not significantly different from the average 
value (= 310) of the 20 stomach cancer cell lines in 
Sanger’s set (P . 0.01). In conclusion, based on our 
initial analysis, there is no significant difference of 
gene linked copy number breakpoints between pri-
mary cancer samples and related cancer cell line.
It was suggested that common chromatin structures 
at breakpoint cluster regions may lead to chromo-
somal translocations found in chronic and acute leu-
kemias.26 These chromatin structural elements include 
topo II and DNase I cleavage sites, scaffold attach-
ment regions (SARs) and lowest free energy level 
sites. Such elements have previously been shown to 
co-localize with genomic breakpoints of chromosome 
translocation in leukemia, suggesting their potential 
involvement in non-homologous recombination.26,27 
SARs, topo II and DNase I sites were found to be 
dispersed throughout the genome every 60–100 kb. 
It is of interest whether these chromatin structural 
elements play a role in the progression of other can-
cer types. Incorporating the genomic position of those 
sites,  together  with  the  copy  number  breakpoints, 
may help in better defining the translocation events 
and delineating the underlying mechanisms.
Recent  reports  in  the  New  England  Journal  of 
Medicine demonstrated that the ALK inhibitor crizo-
tinib yielded a stunning overall response rate of 55% 
and an estimated 6 month, progression-free survival 
rate of 72% in NSCLC patients.28,29 Remarkably, it 
took less than three years from the finding of rear-
rangement of ALK in NSCLC to translate this into a 
clinic therapy, with the repositioning of an existing 
ALK  inhibitor  in  development.30  This  prompts  the 
use of genome-wide analysis to identify new gene 
mutations,  which  will  not  only  help  us  to  identify 
potential novel targets for specific cancers in the con-
text of personalized medicine, but also facilitate the 
repositioning of drugs either already on the market or 
in  development  for  new  purposes.  Next-generation 
sequencing is likely powerful enough to detect differ-
ent kinds of gene mutations, including new variant and 
fusion genes. However, generating the data, as well as 
performing correct gene mapping and alignment, are 
not trivial tasks and will take time to be practiced in 
the patient population. Our analysis reveals the util-
ity of SNP array data that can serve as a complemen-
tary data set and assist in the identification of genetic 
translocations  associated  with  the  tumorigenesis 
process. High density SNP array profiles have been 
generated extensively in the past few years. Querying 
GEO  pubic  database  (http://www.ncbi.nlm.nih.gov/
geo/) alone for Affymetrix and Illumina 1 million SNP 
array profiles have identified ∼4000 samples, and most 
of them are cancer related. For The Cancer Genome 
Atlas project at NCI, the goal is to provide compre-
hensive genomic characterization and sequencing to 
the research community on at least 3,000 new cancer 
cases by the fall of 2011, which includes high density 
SNP array profiling. The vast amount data provide 
us a great resource and opportunity to evaluate the 
known fusions: for their prevalence in a specific can-
cer type, as well as the presence and prevalence across 
different cancers. This type of data also has the poten-
tial utility to predict novel fusions for oncogenes and 
to  prioritize  the  fusion  candidates  to  be  validated 
  experimentally. Recently shown by Berger et al, inte-
grative analysis of transcriptomic and SNP array data 
indicates that there are clear changes in DNA copy num-
ber, with well defined breakpoints evident within both 
partner genes in six out of eight melanoma fusions.31 
This further   supports the   utility of SNP array data in 
fusion gene identification. In conclusion, thousands 
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of publicly available high-density SNP array datasets 
have provided us useful information regarding genes 
with aberrant copy numbers. However, less attention 
has been paid to those genes containing copy number 
breakpoints, or at the border of a CNV. Our evalu-
ation indicates that genes with copy number break-
points are represented at much higher level in cancer 
versus normal cells. These genes are worthy of fur-
ther studies aimed at elucidating the functional con-
sequences of these somatic alterations with respect to 
tumor progression.
Methods
gene position on the chromosome
For each gene, the transcript start and end positions, as 
well as the coding start and end positions, were retrieved 
from the hg18 human genome assembly RefGene table. 
In the case of genes with multiple splice transcripts, the 
transcript start position was based on the first transcript 
start site, and the transcript end position was based on 
the last transcript end site on the chromosome. Genes 
were excluded from analysis if any of the following 
criteria were met: (1) transcripts annotations were on 
different chromosomes, or on un-assembled segments; 
(2) genes were on either the X or Y chromosomes; (3) 
the transcript sequence length was less than 0. Based on 
the hg18 RefGene table, 19,642 genes meet the above 
criteria, and among them, 224 genes were annotated 
as oncogenes based on Affymetrix “HG-U133_Plus_2.
na27.annot.txt” annotation table. For genes with mul-
tiple splice transcripts, the start position for the coding 
sequences was based on the last start site, and the end 
position was based on the first end site on the chro-
mosome, provided that the resulting coding sequence 
length was larger than 0. There are total 17,609 genes 
in the genome that meet these criteria, and 205 genes 
were annotated as oncogenes.
SNP array data analysis
SNP  array  data  were  analyzed  using  Affymetrix 
Genotyping Console 3.0.2 and Birdseed v2 genotype 
algorithm. All of the arrays passed quality control 
requirements, with contrast QC and MAPD values 
within boundaries. If there were no paired samples, 
samples were normalized against default Affymetrix 
normal samples. For the copy number analysis, we 
used regional GC correction and required 5 markers 
to be found within the changed region and the size of 
the region to be at least 100 kb. Genotyping   Console 
Browser  (Affymetrix)  was  used  to  illustrate  copy 
number changes detected.
SNP array data of 820 cell lines, kindly provided 
by Sanger Institute, were profiled on the Affymetrix 
SNP Array 6.0 set.
SNP array data of 38 unique HapMap normal cell 
lines  downloaded  from  GEO  (datasets  GSE15096 
and  GSE17359),  were  profiled  on  the  Affymetrix 
SNP Array 6.0 set.
SNP array data of 20 paired prostate tumor samples 
with matched normal samples were downloaded from 
GEO (GSE12702), and were profiled on the Affyme-
trix Mapping 500 K Array set. Samples were normal-
ized against the matched normal samples.
SNP array data of 25 GIST cancer samples were 
downloaded from GEO (dataset GSE20709) and were 
profiled on the Affymetrix SNP Array 6.0 set.
Searching for genes containing copy 
number breakpoint
For each sample, a segment reporting file was exported 
from Affymetrix  Genotyping  Console  3.0.2,  which 
contains CNV segment information, including copy 
number state, chromosome location, start position, and 
end position. The information was utilized to search 
for copy number breakpoint in an interested gene.
Simulation
In order to evaluate the probability of finding, by ran-
dom chance, a start/end point of a CNV segment that 
falls inside a gene of interest in a specific cell line, 
a simulation was performed as following: 1. For a 
defined cell line, extract the information of all CNV 
segments, such as size, copy number status (gain or 
loss). 2. Randomly assign the CNV segments, with the 
defined size, gain/loss status, to a hypothetical human 
genome, avoiding generating CNV segment overlaps. 
3. Examine whether there is a start/end point of a CNV 
segment that falls inside the gene(s) of interested. 4. 
Repeat steps 1–3 for 100,000 iterations. 5. Calculate 
P values based on the number of iterations required to 
identify a CNV inside the gene(s) of interest based on 
the above criteria, per 100,000 iterations.
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supplemental Table 1. Oncogenes that contain copy number breakpoints in eight CML cell lines.
notes: Breakpoint is within the transcript, regardless of the location or whether it was associated with amplification or deletion. 
supplemental Table 2. Oncogenes that contain copy number breakpoints in 20 prostate cancer samples. 
notes: Breakpoint is within the transcript, regardless of the location or whether it was associated with amplification or deletion.
supplemental Table 3. Oncogenes that contain copy number breakpoints in 140 lung cancer cell lines. 
notes: Breakpoint is within the transcript, regardless of the location or whether it was associated with amplification or deletion. 
supplemental Table 4. Oncogenes that contain copy number breakpoints in Sanger’s 820 cancer cell lines.
notes: Breakpoint is within the transcript, and copy number of the coding region is either remained normal or amplified, but not deleted.
supplemental Table 5. Top ten genes that contain copy number breakpoints in Sanger’s 820 cancer cell lines,  
and not in 38 hapmap normal cell lines.
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